Advertisement
Canadian Journal of Cardiology

Empagliflozin 25mg in Heart Failure With Preserved Ejection Fraction: A Pilot Study

Published:January 25, 2023DOI:https://doi.org/10.1016/j.cjca.2023.01.019
      Empagliflozin is not only able to decrease blood glucose, but also can be used to treat heart failure (HF).
      • Packer M.
      • Anker S.D.
      • Butler J.
      • et al.
      Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
      ,
      • Anker S.D.
      • Butler J.
      • Filippatos G.
      • et al.
      Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
      Clinical studies suggested that empagliflozin 25 mg is superior to 10 mg for patients with HF with reduced ejection fraction (HFrEF).
      • Hao Z.
      • Zhang Y.
      Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction.
      ,
      • Hao Z.
      • Zhang Y.
      Different Doses of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction.
      However, it was unclear if there are differences in the impacts of 10mg and 25mg of empagliflozin on the outcomes of patients with HF with preserved ejection fraction (HFpEF). The aim of this study was to compare the efficacy of different doses of empagliflozin in HFpEF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Packer M.
        • Anker S.D.
        • Butler J.
        • et al.
        Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
        N Engl J Med. 2020; 383: 1413-1424
        • Anker S.D.
        • Butler J.
        • Filippatos G.
        • et al.
        Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
        N Engl J Med. 2021; 385: 1451-1461
        • Hao Z.
        • Zhang Y.
        Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction.
        Can J Cardiol. 2022; 38: 1641-1642
        • Hao Z.
        • Zhang Y.
        Different Doses of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction.
        Int Heart J. 2022; 63: 852-856